BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24114735)

  • 1. Additive effect of the AZGP1, PIP, S100A8 and UBE2C molecular biomarkers improves outcome prediction in breast carcinoma.
    Parris TZ; Kovács A; Aziz L; Hajizadeh S; Nemes S; Semaan M; Forssell-Aronsson E; Karlsson P; Helou K
    Int J Cancer; 2014 Apr; 134(7):1617-29. PubMed ID: 24114735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of gene dosage and gene expression patterns in diploid breast carcinoma.
    Parris TZ; Danielsson A; Nemes S; Kovács A; Delle U; Fallenius G; Möllerström E; Karlsson P; Helou K
    Clin Cancer Res; 2010 Aug; 16(15):3860-74. PubMed ID: 20551037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of UBE2C protein as a prognostic marker in node-positive breast cancer.
    Loussouarn D; Campion L; Leclair F; Campone M; Charbonnel C; Ricolleau G; Gouraud W; Bataille R; Jézéquel P
    Br J Cancer; 2009 Jul; 101(1):166-73. PubMed ID: 19513072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated S100A8 protein expression in breast cancer cells and breast tumor stroma is prognostic of poor disease outcome.
    Miller P; Kidwell KM; Thomas D; Sabel M; Rae JM; Hayes DF; Hudson BI; El-Ashry D; Lippman ME
    Breast Cancer Res Treat; 2017 Nov; 166(1):85-94. PubMed ID: 28717852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer.
    Kariri Y; Toss MS; Alsaleem M; Elsharawy KA; Joseph C; Mongan NP; Green AR; Rakha EA
    Breast Cancer Res Treat; 2022 Apr; 192(3):529-539. PubMed ID: 35124721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer.
    Fristrup N; Birkenkamp-Demtröder K; Reinert T; Sanchez-Carbayo M; Segersten U; Malmström PU; Palou J; Alvarez-Múgica M; Pan CC; Ulhøi BP; Borre M; Ørntoft TF; Dyrskjøt L
    Am J Pathol; 2013 Feb; 182(2):339-49. PubMed ID: 23201130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Derlin-1 exhibits oncogenic activities and indicates an unfavorable prognosis in breast cancer.
    Zeng J; Tian Q; Zeng Z; Cai J; Ye M; Liu Y; Liu A
    Cell Biol Int; 2020 Feb; 44(2):593-602. PubMed ID: 31670413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma.
    Stavnes HT; Nymoen DA; Langerød A; Holth A; Børresen Dale AL; Davidson B
    Virchows Arch; 2013 Feb; 462(2):163-73. PubMed ID: 23242172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ubiquitin-conjugating enzyme UBE2C is highly expressed in breast microcalcification lesions.
    Chou CP; Huang NC; Jhuang SJ; Pan HB; Peng NJ; Cheng JT; Chen CF; Chen JJ; Chang TH
    PLoS One; 2014; 9(4):e93934. PubMed ID: 24699941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH.
    Yun SJ; Yan C; Jeong P; Kang HW; Kim YH; Kim EA; Lee OJ; Kim WT; Moon SK; Kim IY; Choi YH; Kim WJ
    Ann Surg Oncol; 2015 Jul; 22(7):2439-45. PubMed ID: 25348783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DC-SCRIPT: nuclear receptor modulation and prognostic significance in primary breast cancer.
    Ansems M; Hontelez S; Looman MW; Karthaus N; Bult P; Bonenkamp JJ; Jansen JH; Sweep FC; Span PN; Adema GJ
    J Natl Cancer Inst; 2010 Jan; 102(1):54-68. PubMed ID: 20008677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression.
    Ieta K; Ojima E; Tanaka F; Nakamura Y; Haraguchi N; Mimori K; Inoue H; Kuwano H; Mori M
    Int J Cancer; 2007 Jul; 121(1):33-8. PubMed ID: 17354233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactin Induced Protein (PIP) is a potential biomarker for early stage and malignant breast cancer.
    Gangadharan A; Nyirenda T; Patel K; Jaimes-Delgadillo N; Coletta D; Tanaka T; Walland AC; Jameel Z; Vedantam S; Tang S; Mannion C; Lee GY; Goy A; Pecora A; Suh KS
    Breast; 2018 Jun; 39():101-109. PubMed ID: 29656222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma.
    Albertus DL; Seder CW; Chen G; Wang X; Hartojo W; Lin L; Silvers A; Thomas DG; Giordano TJ; Chang AC; Orringer MB; Bigbee WL; Chinnaiyan AM; Beer DG
    J Thorac Oncol; 2008 Nov; 3(11):1236-44. PubMed ID: 18978557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ubiquitin-conjugating enzyme E2C: a potential cancer biomarker.
    Xie C; Powell C; Yao M; Wu J; Dong Q
    Int J Biochem Cell Biol; 2014 Feb; 47():113-7. PubMed ID: 24361302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis.
    Kristensen G; Berg KD; Toft BG; Stroomberg HV; Nolley R; Brooks JD; Brasso K; Roder MA
    J Clin Pathol; 2019 Oct; 72(10):696-704. PubMed ID: 31331953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer.
    Zhang AY; Grogan JS; Mahon KL; Rasiah K; Sved P; Eisinger DR; Boulas J; Vasilaris A; Henshall SM; Stricker PD; Kench JG; Horvath LG
    Ann Oncol; 2017 Aug; 28(8):1903-1909. PubMed ID: 28486686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AZGP1 inhibits soft tissue sarcoma cells invasion and migration.
    Liu J; Han H; Fan Z; El Beaino M; Fang Z; Li S; Ji J
    BMC Cancer; 2018 Jan; 18(1):89. PubMed ID: 29357838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New methods to improve the safety assessment of cryopreserved ovarian tissue for fertility preservation in breast cancer patients.
    Rodríguez-Iglesias B; Novella-Maestre E; Herraiz S; Díaz-García C; Pellicer N; Pellicer A
    Fertil Steril; 2015 Dec; 104(6):1493-502.e1-2. PubMed ID: 26364839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of S100A8 expression on kidney cancer progression and molecular docking studies for kidney cancer therapeutics.
    Mirza Z; Schulten HJ; Farsi HM; Al-Maghrabi JA; Gari MA; Chaudhary AG; Abuzenadah AM; Al-Qahtani MH; Karim S
    Anticancer Res; 2014 Apr; 34(4):1873-84. PubMed ID: 24692722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.